To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
Yomiuri Shimbun file photo Vaccines developed by Pfizer Inc.
The Yomiuri Shimbun
17:01 JST, October 9, 2022
One in four people develop a fever of 37.5 C or higher following a fourth shot of Pfizer Inc.’s coronavirus vaccine, according to an interim report by a team from Juntendo University and other institutions.
However, the frequency of major side effects tends to be lower compared with those following a third inoculation. The team reported their findings Friday to an expert panel of the Health, Labor and Welfare Ministry.
Of 1,490 health care workers and others who received a fourth Pfizer shot, 26% registered a fever of 37.5 C or higher within a week, while 14% had a fever of 38 C or higher.
The interim report says 40% of people logged a fever of 37.5 C or higher after a third shot of the vaccine, while 21% saw the mercury rise to 38 C or higher. The percentage of people who developed a fever tended to be lower following the fourth inoculation.
The team also examined the effects of a fourth dose of the vaccine made by U.S. firm Moderna Inc. Of 690 patients, 39% had a fever of 37.5 C or higher, while 22% experienced temperatures of 38 C or more.
As with the Pfizer product, the percentage of those who developed a fever tended to be lower after a third shot of the Moderna vaccine.
